title: Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
authors: German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.
authors: V
authors: V
authors: Goede
authors: German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.
authors: K
authors: K
authors: Fischer
authors: German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.
authors: A
authors: A
authors: Engelke
authors: Oncology Practice, Würzburg, Germany.
authors: R
authors: R
authors: Schlag
authors: Department of Hematology, Centre Henri Becquerel, Rouen, France.
authors: S
authors: S
authors: Lepretre
authors: Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain.
authors: L F C
authors: LF
authors: Montero
authors: Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy.
authors: M
authors: M
authors: Montillo
authors: Department of Hematology, University Hospital of Wales, Cardiff, UK.
authors: C
authors: C
authors: Fegan
authors: F. Hoffmann-La Roche Ltd, Basel, Switzerland.
authors: E
authors: E
authors: Asikanius
authors: F. Hoffmann-La Roche Ltd, Welwyn, UK.
authors: K
authors: K
authors: Humphrey
authors: F. Hoffmann-La Roche Ltd, Basel, Switzerland.
authors: G
authors: G
authors: Fingerle-Rowson
authors: 1] German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany [2] Cluster of Excellence 'Cellular Stress Responses in Aging Associated Diseases' (CECAD), University of Cologne, Cologne, Germany.
authors: M
authors: M
authors: Hallek
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D000069283:Rituximab; D015996:Survival Rate
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D002699:Chlorambucil; D000069283:Rituximab; C543332:obinutuzumab
references: Lancet Oncol. 2014 Sep;15(10):1090-9
references: 25150798
references: Br J Haematol. 2011 Feb;152(3):295-306
references: 21155758
references: Blood. 2008 Aug 15;112(4):975-80
references: 18411418
references: Mol Cancer Ther. 2013 Oct;12 (10 ):2031-42
references: 23873847
references: Blood. 2008 Jun 15;111(12):5446-56
references: 18216293
references: J Am Geriatr Soc. 1995 Feb;43(2):130-7
references: 7836636
references: Lancet Oncol. 2014 Jan;15(1):48-58
references: 24332241
references: N Engl J Med. 2014 Mar 20;370(12):1101-10
references: 24401022
references: Nephron. 1976;16(1):31-41
references: 1244564
references: Blood. 2010 Jun 3;115(22):4393-402
references: 20194898
references: Lancet. 2010 Oct 2;376(9747):1164-74
references: 20888994
references: N Engl J Med. 2014 Mar 13;370(11):997-1007
references: 24450857
references: N Engl J Med. 2014 Jul 17;371(3):213-23
references: 24881631